Serotonin and anxiety: Current models

International Clinical Psychopharmacology

Volumn 15, Issue SUPPL. 2, 2000, Pages

  Stein, D J ^a   Stahl, S ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

Anxiety disorder; Selective serotonin reuptake inhibitor; Serotonin

Indexed keywords

BENZODIAZEPINE DERIVATIVE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ANXIETY NEUROSIS; CONFERENCE PAPER; OBSESSION; PANIC; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; SEROTONINERGIC SYSTEM; SOCIAL PHOBIA;

EID: 0033736596     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200008002-00002     Document Type: Conference Paper

References (37)

1. Cingulotomy for intractable obsessive-compulsive disorder. Prospective long-term follow-up of 18 patients
2. Association of road-traffic accidents with benzodiazepine use
3. Prolactin and cortisol responses to MK-212, a serotonin agonist, in obsessive-compulsive disorder
4. Caudate glucose metabolic rate changes with both drug and behavior therapy for OCD
5. Fluoxetine: A review of receptor and functional effects and their clinical implications
6. Neurological soft signs in obsessive-compulsive disorder
7. Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: A meta-analysis
8. Serotonin-related function in panic disorder: A critical overview
9. Clinical improvement with fluoxetine therapy and noradrenergic function in patients with panic disorder
10. Obsessive-compulsive disorder in Huntington's disease
11. The role of the amygdala in fear and anxiety
12. 5-HT and mechanisms of defence
13. Economic costs of anxiety disorders
14. Alteration of serotonin release in the guinea pig orbito-frontal cortex by selective serotonin reuptake inhibitors
15. Behavioral and endocrine responses to clomipramine in panic disorder patients with or without alcoholism
16. 5-Hydroxytryptamine pathways in anxiety and its treatment
17. Signs of central nervous system dysfunction in obsessive-compulsive disorder
18. Initiation and adaptation: A paradigm for understanding psychotropic drug action
19. 5-HT and anxiety
20. Neuroendocrine evidence for serotonin receptor hypersensitivity in panic disorder
21. Clinical utility of the selective serotonin reuptake inhibitors in the spectrum of anxiety
22. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey
23. Obsessive-compulsive disorder: Is there a frontal lobe dysfunction?
24. Different projections of the central amygdaloid nucleus mediate autonomic and behavioral correlates of conditioned fear
25. Obsessive compulsive disorder is not an anxiety disorder
26. Mechanisms of action of selective serotonin reuptake inhibitors in the treatment of psychiatric disorders
27. Neuroimaging in obsessive-compulsive disorder and related disorders
28. Studies of the nucleus locus coeruleus in monkeys and hypotheses for neuropsychopharmacology
29. The psychology of perseverative and stereotyped behavior
30. Reconciling the role of central serotonin neurones in human and animal behavior
31. Mechanism of action of serotonin selective reuptake inhibitors: Serotonin receptors and pathways mediate therapeutic effects and side effects
32. Meta-analysis of pharmacotherapy trials for obsessive compulsive disorder
33. Single photon emission computed tomography of the brain with tc-99m HMPAO during sumatriptan challenge in obsessive-compulsive disorder: Investigating the functional role of the serotonin auto-receptor
34. Clomipramine treatment of obsessive-compulsive disorder. II. Biochemical aspects
35. Serotonin-related, anxiety/aggressiondriven, stressor-precipitated depression: A psychobiological hypothesis
36. Pharmacological challenges in OCD